Search

for
Search:

GlossaryWarts (Verruca)

small, rough skin growths caused by human papillomavirus (HPV)

Warts, also known as verrucae, are small, rough growths on the skin caused by the human papillomavirus (HPV). They are typically non-cancerous and can appear on various parts of the body, including the hands, feet, and genitals. Warts are contagious and can spread through direct contact with an infected person or surface.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 631 results

research A Case Report of Verruca Vulgaris on Basis of Alopecia Areata Successfully Treated with Diphenylcyclopropenone

1 citations , January 2017 in “International journal of trichology”

Diphenylcyclopropenone (DPCP) effectively treated both alopecia areata and verruca vulgaris.

research Confluent Verruca Vulgaris Arising Within Bilateral Eyebrow Tattoos

2 citations , May 2018 in “Dermatologic Surgery”

research Cutaneous Manifestations of Dabrafenib: A Selective Inhibitor of Mutant BRAF in Patients with Metastatic Melanoma

173 citations , July 2012 in “British Journal of Dermatology”

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

research Change of the Diagnostic Distribution in Applicants to Dermatology After COVID-19 Pandemic: What It Whispers to Us?

21 citations , June 2020 in “Dermatologic Therapy”

The COVID-19 pandemic led to fewer dermatology visits and changed the types of skin conditions patients experienced.

research Comparison of Patients’ Diagnoses in a Dermatology Outpatient Clinic During the COVID-19 Pandemic Period and Pre-Pandemic Period

16 citations , December 2020 in “International Journal of Clinical Practice”

The pandemic changed how often certain skin conditions were diagnosed.

View more "verruca" in research →

Community Join

1 / 1 results

community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

in Treatment 30 upvotes 2 months ago

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.